Previous Studies





Management Team


Contact Us


Travel Directions


Please click  here to download our brochure.

 Medicines Evaluation Unit - Previous Studies - Publications

Original Research (peer reviewed)          

  1. Fujimori T, Grabiec AM, Kaur M, Bell TJ, Fujino N, Cook PC, Svedberg FR, MacDonald AS, Maciewicz RA, Singh D, Hussell T. The Axl receptor tyrosine kinase is a discriminator of macrophage function in the inflamed lung. Mucosal Immunol. 2015 Jan 21. doi: 10.1038/mi.2014.129. [Epub ahead of print]

  2. Gupta V, Banyard A, Mullan A, Sriskantharajah S, Southworth T, Singh D.  Characterisation of the inflammatory response to inhaled LPS in mild to moderate COPD. Br J Clin Pharmacol. 2014 Nov 7. doi: 10.1111/bcp.12546. [Epub ahead of print]

  3. Zhang WJ, Hubbard Cristinacce PL, Bondesson E, Nordenmark LH, Young SS, LiuYZ, Singh D, Naish JH, Parker GJ. MR Quantitative Equilibrium Signal Mapping: AReliable Alternative to CT in the Assessment of Emphysema in Patients with Chronic Obstructive Pulmonary Disease. Radiology. 2015 Jan 7:132953. [Epub ahead of print]

  4. Castaldi PJ, Cho MH, Zhou X, Qiu W, Mcgeachie M, Celli B, Bakke P, Gulsvik A, Lomas DA, Crapo JD, Beaty TH, Rennard S, Harshfield B, Lange C, Singh D, Tal-Singer R, Riley JH, Quackenbush J, Raby BA, Carey VJ, Silverman EK, Hersh CP. Genetic control of gene expression at novel and stablished chronic obstructive pulmonary disease loci. Hum Mol Genet. 2014 Oct 14. pii: ddu525. [Epub ahead of print]

  5. Lea S, Harbron C, Khan N, Booth G, Armstrong J, Singh D.  Corticosteroid insensitive alveolar macrophages from asthma patients; synergistic interaction with a p38 MAPK inhibitor. Br J Clin Pharmacol. 2014 doi: 10.1111/bcp.12536. [Epub ahead of print]

  6. Kaur M, Reynolds S, Smyth LJ, Simpson K, Hall S, Singh D. The effects of corticosteroids on cytokine production from asthma lung lymphocytes. Int Immunopharmacol. 2014 ;23:581-4.

  7. Singh D, Pujol H, Ribera A, Seoane B, Massana E, Astbury C, Ruiz S, de Miquel G. A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting beta2-adrenergic agonist, in asthma; a Phase II, randomized study. BMC Pulm Med. 2014;14:176.

  8. Leaker BR, Singh D, Ali FY, Barnes PJ, O'Connor B. The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma. BMC Pulm Med. 2014;14:166.

  9. Jones PW, Lamarca R, Chuecos F, Singh D, Agustí A, Bateman ED, de Miquel G, Caracta C, Garcia Gil E. Characterisation and impact of reported and unreported exacerbations: results from ATTAIN. Eur Respir J. 2014;44:1156-65.

  10. Khurana S, Ravi A, Sutula J, Milone R, Williamson R, Plumb J, Vestbo J, Singh D. Clinical characteristics and airway inflammation profile of COPD persistent sputum producers. Respir Med. 2014;108:1761-1770

  11. Singh D, Jones PW, Bateman ED, Korn S, Serra C, Molins E, Caracta C, Gil EG, Leselbaum A. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014;14:178

  12. Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R; ECLIPSE investigators. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014;44:1697-700

  13. Singh D, Fox SM, Tal-Singer R, Bates S, Riley JH, Celli B.  Altered gene expression in blood and sputum in COPD frequent exacerbators in the ECLIPSE cohort. PLoS One. 2014;9:e107381.

  14. Leaker BR, Barnes PJ, Jones CR, Tutuncu A, Singh D. Efficacy and safety of nebulised glycopyrrolate for administration using high efficiency nebuliser in patients with COPD. Br J Clin Pharmacol. 2014 Sep 22. doi: 10.1111/bcp.12517. [Epub ahead of print]

  15. Singh DZhu CQSharma SChurch AKalberg CJ. Daily variation in lung function in COPD patients with combined albuterol and ipratropium: Results from a 4-week, randomized, crossover study. Pulm Pharmacol Ther. 2014 Sep 6. pii: S1094-5539(14)00109-6. doi: 10.1016/j.pupt.2014.08.010. [Epub ahead of print]

  16. Ravi AK, Khurana S, Lemon J, Plumb J, Booth G, Healy L, Catley M, Vestbo J, Singh D. Increased levels of soluble interleukin-6 receptor and CCL3 in COPD sputum. Respir Res. 2014;15:103.

  17. Morgan AR, Parker GJ, Roberts C, Buonaccorsi GA, Maguire NC, Hubbard Cristinacce PL, Singh D, Vestbo J, Bjermer L, Jögi J, Taib Z, Sarv J, Bruijnzeel PL, Olsson LE, Bondesson E, Nihlén U, McGrath DM, Young SS, Waterton JC, Nordenmark LH. Feasibility assessment of using oxygen-enhanced magnetic resonance imaging for evaluating the effect of pharmacological treatment in COPD. Eur J Radiol. 2014;83:2093-101

  18. Wedzicha JA, Singh D, Vestbo J, Paggiaro PL, Jones PW, Bonnet-Gonod F, Cohuet G, Corradi M, Vezzoli S, Petruzzelli S, Agusti A; FORWARD Investigators. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir Med. 2014;108:1153-62.

  19. Lee WY, Southworth T, Booth S, Singh D. High and low dose allergen challenges in asthma patients using inhaled corticosteriods. Br J Clin Pharmacol. 2014 Sep 11. doi: 10.1111/bcp.12508. [Epub ahead of print]

  20. Rossall MR, Cadden PA, Molphy SD, Plumb J, Singh D. Repeatability of induced sputum measurements in moderate to severe asthma. Respir Med. 2014;108:1566-8

  21. Diamant Z, Sidharta PN, Singh D, O'Connor BJ, Zuiker R, Leaker BR, Silkey M, Dingemanse J. Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy. 2014;44:1044-52

  22. Chawes BL, Govoni M, Kreiner-Møller E, Vissing NH, Poorisrisak P, Mortensen L, Nilsson E, Bisgaard A, Dossing A, Deleuran M, Skytt NL, Samandari N, Piccinno A, Sergio F, Ciurlia G, Poli G, Acerbi D, Singh D, Bisgaard H. Systemic exposure to inhaled beclometasone/formoterol DPI is age and body size dependent. Respir Med. 2014;108:1108-16

  23. Djukanović R, Harrison T, Johnston SL, Gabbay F, Wark P, Thomson NC, Niven R, Singh D, Reddel HK, Davies DE, Marsden R, Boxall C, Dudley S, Plagnol V, Holgate ST, Monk P. The Effect of Inhaled Interferon-beta on Worsening of Asthma Symptoms Caused by Viral Infections: a Randomised Trial. Am J Respir Crit Care Med. 2014;190:145-54.

  24. Govoni M, Piccinno A, Lucci G, Poli G, Acerbi D, Baronio R, Singh D, Kuna P, Chawes BL, Bisgaard H. The systemic exposure to inhaled beclometasone/formoterol pMDI with valved holding chamber is independent of age and body size. Pulm Pharmacol Ther. 2014 Apr 16. pii: S1094-5539(14)00041-8. doi: 10.1016/j.pupt.2014.04.003. [Epub ahead of print]

  25. Metcalfe HJ, Lea S, Hughes D, Khalaf R, Abbott-Banner K, Singh D. Effects of cigarette smoke on Toll-like receptor (TLR) activation of chronic obstructive pulmonary disease (COPD) macrophages. Clin Exp Immunol. 2014;176:461-72

  26. Higham A, Lea S, Ray D, Singh D. Corticosteroid effects on COPD alveolar macrophages: dependency on cell culture methodology. J Immunol Methods. 2014;405:144-53

  27. Singh D, Nicolini G, Bindi E, Corradi M, Guastalla D, Kampschulte J, Pierzchała W, Sayiner A, Szilasi M, Terzano C, Vestbo J; FUTURE (Foster Upgrades TherapeUtic care in REspiratory disease) study group. Extrafine Beclomethasone/formoterol compared to Fluticasone/salmeterol Combination Therapy in COPD. BMC Pulm Med. 2014;14:43

  28. Lea S, Plumb J, Metcalfe H, Spicer D, Woodman P, Fox JC, Singh D. The effect of PPAR-γ ligands on in vitro and in vivo models of COPD. Eur Respir J. 2014;43:409-20

  29. Grundy S, Kaur M, Plumb J, Reynolds S, Hall S, House D, Begg M, Ray D, Singh D. CRAC channel inhibition produces greater anti-inflammatory effects than glucocorticoids in COPD CD8 cells. Clin Sci (Lond). 2014;126:223-32

  30. Franciosi  LG, Diamant Z, Banner KH, Zuiker R, Morelli N, Kamerling IM, de Kam ML, Burggraaf J, Cohen AF, Cazzola M, Calzetta L, Singh D, Spina D, Walker MJ, Page CP.  Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir Med. 2013;1:714-27.

  31. Singh D, Boyce M, Norris V, Kent SE, Bentley JH. Inhibition of the early asthmatic response to inhaled allergen by the 5-lipoxygenase activating protein inhibitor GSK2190915: a dose-response study. Int J Gen Med. 2013;6:897-903

  32. Higham A, Lea S, Plumb J, Maschera B, Simpson K, Ray D, Singh D. The role of the liver X receptor in chronic obstructive pulmonary disease. Respir Res. 2013;14:106

  33. Kaur M, Singh D. Neutrophil Chemotaxis Caused by Chronic Obstructive Pulmonary Disease Alveolar Macrophages: The Role of CXCL8 and the Receptors CXCR1/CXCR2. J Pharmacol Exp Ther. 2013;347:173-80

  34. Grundy S, Plumb J, Lea S, Kaur M, Ray D, Singh D. Down regulation of T cell receptor expression in COPD pulmonary CD8 cells. PLoS One. 2013 19;8:e71629

  35. Gaffey K, Reynolds S, Plumb J, Kaur M, Singh D. Increased phosphorylated p38 mitogen activated protein kinase in COPD lungs. Eur Respir J. 2013 ;42:28-41

  36. Plumb J, Robinson L, Lea S, Banyard A, Blaikley J, Ray D, Bizzi A, Volpi G, Facchinetti F, Singh D. Evaluation of Glucocorticoid Receptor Function in COPD Lung Macrophages Using Beclomethasone-17-Monopropionate. PLoS One. 2013;8:e64257

  37. Aul R, King H, Kolsum U, Singh D. The reproducibility of bolus allergen challenges; power calculations for clinical trials. Eur J Clin Pharmacol. 2013;69:1187-8

  38. Kent SE, Boyce M, Diamant Z, Singh D, O'Connor BJ, Saggu PS, Norris V. The 5-lipoxygenase-activating protein inhibitor, GSK2190915, attenuates the early and late responses to inhaled allergen in mild asthma. Clin Exp Allergy. 2013;43:177-86

  39. Sumner H, Woodcock A, Kolsum U, Dockry R, Lazaar AL, Singh D, Vestbo J, Smith JA. Predictors of objective cough frequency in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187:943-9

  40. Singh D, Kampschulte J, Wedzicha JA, Jones PW, Cohuet G, Corradi M, Higenbottam T, Petruzzelli S, Vestbo J. A trial of beclomethasone/formoterol in copd using exact-pro to measure exacerbations. Eur Respir J. 2013;41:12-7

  41. Singh D, Cadden P, Hunter M, Collins LP, Perkins M, Pettipher R, Townsend E, Vinall S, O'Connor B. Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459. Eur Respir J. 2013;41:46-52

  42. Aul R, Patel S, Summerhill S, Kilty I, Plumb J, Singh D. LPS challenge in healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2. Int Immunopharmacol.2012;13:225-31

  43. Beeh KM, Singh D, Di Scala L, Drollmann A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis. 2012;7:503-13.

  44. Moretto N, Bertolini S, Iadicicco C, Marchini G, Kaur M, Volpi G, Patacchini R, Singh D, Facchinetti F. Cigarette smoke and its component acrolein augment IL-8/CXCL8 mRNA stability via p38 MAPK/MK2 signaling in human pulmonary cells. Am J Physiol Lung Cell Mol Physiol. 2012;303:L929-38.

  45. Basanta M, Ibrahim B, Dockry R, Douce D, Morris M, Singh D, Woodcock A, Fowler SJ. Exhaled volatile organic compounds for phenotyping chronic obstructive pulmonary disease: a cross-sectional study. Respir Res. 2012;13:72

  46. Chaudhuri N, Jary H, Lea S, Khan N, Piddock KC, Dockrell DH, Donaldson K, Duffin R, SinghD, Parker LC, Sabroe I. Diesel exhaust particle exposure in vitro alters monocyte differentiation and function. PLoS One. 2012;7:e51107

  47. Singh D, Corradi M, Bindi E, Baronio R, Petruzzelli S, Paggiaro P. Relief of methacholine-induced bronchospasm with extrafine beclomethasone dipropionate/formoterol in comparison with salbutamol in asthma. Pulm Pharmacol Ther. 2012;25:392-8

  48. Barnes PJ, Nicolini G, Bizzi A, Spinola M, Singh D. Do inhaled corticosteroid/long-acting beta2-agonist fixed combinations provide superior clinical benefits compared with separate inhalers? A literature reappraisal. Allergy Asthma Proc. 2012;33:140-4.

  49. Rossall M, Cadden P, Kolsum U, Singh D. A comparison of the clinical and induced sputum characteristics of early- and late-onset asthma. Lung. 2012;190:459-62

  50. Singh D, Magnussen H, Kirsten A, Mindt S, Caracta C, Seoane B, Jarreta D, Garcia Gil E. A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients. Pulm Pharmacol Ther. 2012;25:248-53. 

  51. Aul R, Armstrong J, Duvoix A, Lomas D, Hayes B, Miller BE, Jagger C, Singh D. Inhaled LPS challenges in smokers: a study of pulmonary and systemic effects. Br J Clin Pharmacol. 2012;74:1023-32

  52. Jones PW, Singh D, Bateman ED, Agusti A, Lamarca R, de Miquel G, Segarra R, Caracta C, Garcia Gil E. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. 2012;40:830-6

  53. Ziegler-Heitbrock L, Frankenberger M, Heimbeck I, Burggraf D, Wjst M, Häussinger K, Brightling C, Gupta S, Parr D, Subramanian D, Singh D, Kolsum U, Boschetto P, Potena A, Gorecka D, Nowinski A, Barta I, Döme B, Strausz J, Greulich T, Vogelmeier C, Bals R, Hohlfeld JM, Welte T, Venge P, Gut I, Boland A, Olaso R, Hager J, Hiemstra P, Rabe KF, Unmüssig M, Müller-Quernheim J, Prasse A.  The EvA study: aims and strategy. Eur Respir J. 2012;40:823-9

  54. Kaur M, Smyth LJ, Cadden P, Grundy S, Ray D, Plumb J, Singh D. T lymphocyte insensitivity to corticosteroids in chronic obstructive pulmonary disease. Respir Res. 2012;13:20. 

  55. Southworth T, Metryka A, Lea S, Farrow S, Plumb J, Singh D. IFNγ synergistically enhances LPS signalling in alveolar macrophages from COPD patients and controls by corticosteroid resistant STAT1 activation. Br J Pharmacol. 2012 ;166: 2070-83

  56. Gibbs JE, Blaikley J, Beesley S, Matthews L, Simpson KD, Boyce SH, Farrow SN, Else KJ, Singh D, Ray DW, Loudon AS. The nuclear receptor REV-ERBα mediates circadian regulation of innate immunity through selective regulation of inflammatory cytokines. Proc Natl Acad Sci U S A. 2012;109:582-7

  57. Plumb J, Gaffey K, Kane B, Malia-Milanes B, Shah R, Bentley A, Ray D, Singh D. Reduced glucocorticoid receptor expression and function in airway neutrophils. Int Immunopharmacol. 2012;12:26-33.

  58. Ibrahim B, Basanta M, Cadden P, Singh D, Douce D, Woodcock A, Fowler SJ. Non-invasive phenotyping using exhaled volatile organic compounds in asthma. Thorax. 2011;66:804-9.

  59. Kay P, Schlossmacher G, Matthews L, Sommer P, Singh D, White A, Ray D. Loss of glucocorticoid receptor expression by DNA methylation prevents glucocorticoid induced apoptosis in human small cell lung cancer cells. PLoS One.2011; 6:e24839.

  60. Singh D, Collarini S, Poli G, Acerbi D, Amadasi A, Rusca A. Effect of AeroChamber Plus™ on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI. Br J Clin Pharmacol. 2011 ;72:932-9

  61. Donohue JF, Singh D, Kornmann O, Lawrence D, Lassen C, Kramer B. Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis. 2011;6:477-92.

  62. Qiu W, Cho MH, Riley JH, Anderson WH, Singh D, Bakke P, Gulsvik A, Litonjua AA, Lomas DA, Crapo JD, Beaty TH, Celli BR, Rennard S, Tal-Singer R, Fox SM, Silverman EK, Hersh CP; ECLIPSE Investigators. Genetics of sputum gene expression in chronic obstructive pulmonary disease. PLoS One. 2011;6:e24395.

  63. Armstrong J, Harbron C, Lea S, Booth G, Cadden P, Wreggett KA, Singh D. Synergistic effects of p38 mitogen-activated protein kinase inhibition with a corticosteroid in alveolar macrophages from patients with chronic obstructive pulmonary disease. J Pharmacol Exp Ther. 2011;338:732-40.

  64. Singh SD, Fox SM, Tal-Singer R, Plumb J, Bates S, Broad P, Riley JH, Celli B. Induced Sputum Genes Associated with Spirometric and Radiological Disease Severity in  COPD ex-smokers. Thorax. 2011;65:764-74

  65. Halpin DMG, Gray J, Edwards SJ, Morais J, Singh SD. Budesonide/formoterol versus salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomized controlled trials. Int J Clin Pract. 2011;66:489-95

  66. Al-Shair K, Kolsum U, Dockry R, Morris J, Singh D, Vestbo J. Biomarkers of systemic inflammation and depression and fatigue in moderate clinically stable COPD. Respir Res. 2011; 5: 3

  67. Eustace A, Smyth L J, Mitchell L, Williamson K, Plumb J, Singh D.  Identification of cells expressing interleukin-17A and F in the lungs of COPD patients. Chest. 2011;139:1089-100.

  68. Kent LM, Fox SM, Farrow SN, Singh D. The effects of dexamethasone on cigarette smoke induced gene expression changes in COPD macrophages. Int Immunopharmacol. 2010:10;57-64

  69. Singh D, Kane B, Molfino NA, Cranmer H, Faggioni R, Roskos L, Woodcock A. Pharmacokinetics of an IL-13 antibody in asthma. BMC Pulm Med.2010;10:3

  70. Singh D, Smyth L, Borrill Z, Sweeney L, Tal-Singer R. A Randomised, Placebo Controlled Study Of The Effects Of The p38 MAPK Inhibitor SB-681323 On Blood Biomarkers Of Inflammation In COPD Patients. J Clin Pharmacol .2010;50:94-100.

  71. Basanta M, Jarvis RM, Xu Y, Blackburn G, Tal-Singer R, Woodcock A, Singh D, Goodacre R, Thomas CL, Fowler SJ. Non-invasive metabolomic analysis of breath using differential mobility spectrometry in patients with chronic obstructive pulmonary disease and healthy smokers. Analyst. 2010;135:315-20

  72. Singh D, Petavy F, Macdonald AJ, Lazaar AL, O’Connor BJ. The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. Respir Res. 2010;11:26

  73. Nicholas B, Howarth P, Guha-Nyogi B, Singh D, Djukanovic R. Identification of Lipocalin and Apolipoprotein A1 as Biomarkers of Chronic Obstructive Pulmonary Disease.  Am J Respir Crit Care Med. 2010;181:1049-60

  74. Berry A, Plumb J, Farrow S, Singh D, Ray D Donn R. Interferon inducible factor 16 (IFI16) is a novel modulator of glucocorticoid action. FASEB. 2010;24:1700-13

  75. Singh D, Edwards L, Tal-Singer R, Rennard S. Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. Respir Res. 2010;11:77

  76. Smyth LJ, Eustace A, Kolsum U, Blaikely J, Singh D. Increased airway T regulatory cells in asthmatic subjects. Chest. 2010;138:905-12

  77. Bateman E, Singh D, Smith D, Disse B, Towes L, Massey D, Blatchford J, Pavia D, Hodder R. Efficacy and safety of tiotropium Respimat® SMI in COPD in two 1-year randomized studies.  Int J Chron Obstruct Pulmon Dis. 2010;5:197–208

  78. Kolsum U, Borrill Z, Roy K, Starkey C, Vestbo J, Houghton C, Singh SD. Impulse oscillometry in COPD: Identification of measurements related to airway obstruction, airway conductance and lung volumes. Respir Med. 2009;103:136-43

  79. Kent L, Smyth L, Plumb J, Clayton C, Fox S, Ray D, Farrow S, Singh SD.  Inhibition of LPS stimulated COPD macrophage inflammatory gene expression by Dexamethasone and the p38 MAPK inhibitor SB706504. J Pharmacol Exp Ther. 2009;328:458-68

  80. Gibbs JE, Beesley S, Plumb J, Singh SD, Farrow S, Ray DW, Loudon AS.  Circadian timing in the lung; a specific role for bronchiolar epithelial cells.  Endocrinology. 2009;150:268-76

  81. Francis H, Colecliff W, Hazell M, Singh D, Niven R, Hagan G, Spencer M, Franks T. Prevalence Of Airflow Obstruction In Patients Attending A Rapid Access Chest Pain Clinic. Respir Med. 2009;103:736-42

  82. Plumb J, Smyth LJC, Adams HR, Vestbo J, Bentley A, Singh SD. Increased T regulatory cells within lymphocyte follicles in moderate COPD.  Eur Respir J. 2009;34:89-94

  83. Kolsum U, Roy K, Starkey C, Borrill Z, Truman N, Vestbo J, Singh D. The Repeatability of Interleukin-6 (IL-6), Tumour necrosis factor - α (TNF-α) and C-reactive protein (CRP) in COPD patients over 1 year. Int J Chron Obstruct Pulmon Dis.2009;4:149-56

  84. Roy K, Smith J, Kolsum U, Borrill Z, Vestbo J, Singh D. COPD phenotype description using principal components analysis. Respir Res. 2009;29:10:41

  85. Lewis S, Singh D, Evans C. Cyclic hydrostatic pressure and cotton particles stimulate synthesis by human lung macrophages of cytokines in vitro. Respir Res. 2009;10:44

  86. Borrill Z, Roy K, Kolsum U, Southworth T, Vestbo J, Singh D. Seretide withdrawal increases airway inflammation in moderate COPD patients. Eur J Clin Pharmacol. 2009;65:1165-6.

  87. Armstrong J, Sargeant C, Singh D. Glucocorticoid Sensitivity Of LPS Stimulated COPD Alveolar Macrophages. Clin Exp Immunol. 2009;158:74-83.

  88. Kane B, Borrill Z, Southworth T, Woodcock A, Singh D. Reduced exhaled breath condensate pH in asthmatic smokers using inhaled corticosteroids. Respirology. 2009;14:419-23.

  89. Moretto N, Facchinetti F, Southworth T, Civelli M, Singh D, Patacchini R. alpha,beta-Unsaturated aldehydes contained in cigarette smoke elicit IL-8 release in pulmonary cells through mitogen-activated protein kinases. Am J Physiol Lung Cell Mol Physiol. 2009;296:L839-48.

  90. Kane B, Kolsum U, Southworth T, Armstrong J, Woodcock A, Singh D. The effects of smoking on the lipopolysaccharide response and glucocorticoid sensitivity of alveolar macrophages of patients with asthma. Chest. 2009;136:163-70. 

  91. Al-shair K, Dockry R, Mallia-Milanes B, Kolsum U, Singh D, Vestbo J. Depression and its relationship with poor exercise capacity, BODE index and muscle wasting in COPD. Respir Med. 2009;103:1572-9.

  92. Al-shair K, Kolsum U, Berry P, Smith J, Caress A, Singh D, Vestbo J. Development, dimensions, reliability and validity of the novel Manchester COPD fatigue scale. Thorax. 2009;64:950-5

  93. Borrill ZL, Houghton CM, Tal-Singer R, Vessey SR, Faiferman I, Langley SJ, Singh SD.  The use of plethysmography and oscillometry to compare long acting bronchodilators in patients with COPD. Br J Clin Pharmacol. 2008;65:244-52

  94. Singh SD, Piccinno A,  Borrill Z, Gianluigi Poli, AcerbiD, Meuleners L, WoodcockAA. Tolerability of high cumulative doses of the HFA modulite beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients. Pulm Pharmacol Ther. 2008;21:551-7

  95. Kent L, Smyth L , Clayton C, Scott L, Cook T, Stephens R, Fox S, Hext P, Farrow S, Singh SD. Cigarette smoke extract induced cytokine and chemokine gene expression changes in COPD Macrophages.  Cytokine. 2008;42:205–216

  96. Borrill ZL, Roy K, Vessey RS, Woodcock AA, Singh SD.  Non-invasive biomarkers and pulmonary function in smokers. Int J Chron Obstruct Pulmon Dis. 2008;3:171-83

  97. Singh SD, Fairwood J, Murdoch R, Weeks A, Russell P, Roy K, Langley S, Woodcock A. The reproducibility of adenosine monophosphate bronchial challenges in mild, steroid-naive asthmatics. Br J Clin Pharmacol. 2008;66:261-5

  98. Singh SD, Brooks J, Hagan G, Cahn A, O'Connor B. ‘Triple’ therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax. 2008;63:592-8.

  99. Rice L, Waters CE, Eccles J, Garside H, Sommer P, Kay P, Blackhall FH, Zeef L, Telfer B, Stratford I, Clarke R, Singh SD, Stevens A, White A, Ray D W. Identification, and functional analysis of Ska2 interaction with the glucocorticoid receptor.  J  Endocrinol. 2008;198:499-509.

  100. Kirkham S, Kolsum U, Rousseau K, Singh SD, Vestbo J, Thornton DJ.   MUC5B is the Major Mucin in the Gel-phase of Sputum in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2008;178:1033-9.

  101. Smyth LJ, Starkey C, Gordon FS, Vestbo J, Singh SD. CD8 chemokine receptors in chronic obstructive pulmonary disease. Clin Exp Immunol. 2008;154:56-63

  102. Basanta M, Koimtzis T, Singh SD, Wilson I, Thomas CLP ,  An adaptive breath sampler for use with human subjects with an impaired respiratory function. Analyst. 2007;2:153-163
  103. Basanta M, Singh SD, Fowler S, Wilson I, Dennis R, Thomas CL. Increasing analytical space in gas chromatography-differential mobility spectrometry with dispersion field amplitude programming. J Chromatogr A. 2007;1173:129-38

  104. Roy K, Borrill ZL, Starkey C, Hazel AL, Morris J, Vestbo J, Singh SD. Use of different exhaled nitric oxide multiple flow rate models in COPD.Eur Respir J.2007;29:651-659.

  105. Borrill ZL, Starkey RC, Singh SD.  Variability of exhaled breath condensate leukotriene B4 and 8-isoprostane of COPD. Int J Chron Obstruct Pulmon Dis. 2007;2:71-76

  106. Houghton CM, Lawson N, Borrill ZL, Wixon C L, Yoxall SQ, Langley SJ, Woodcock AA, Singh SD. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respir Res. 2007;8:52

  107. Singh SD, Richards D, Knowles RG, Schwartz S, Woodcock AA, Langley SJ, O’Connor BJ. Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma.  Am J Respir Crit Care Med. 2007:176;988-93

  108. Singh SD, Tutuncu A, Lohr I, Carlholm M, Polanowski T. Budesonide administered using chlorofluorocarbon and hydrofluoroalkane pressurized metered-dose inhalers; pharmacokinetics, pharmacodynamics and clinical equivalence. Int J Clin Pharmacol Ther. 2007;45:485-495

  109. Borrill ZL, Clough D, Truman N, Morris J, Langley SJ, Singh SD. A comparison of exhaled nitric oxide measurements performed using 3 different analysers. Respir Med. 2006;100:1392-6

  110. Singh SD, Tal-Singer R, Faiferman I,Lasenby S, Henderson A,Wessels D, Goosen A, Dallow N, Vessey R,Goldman M. Plethysmography And Impulse Oscillometry Assessment Of Tiotropium And Ipratropium Bromide; A Randomised, Double Blind, Placebo Controlled, Crossover Study In Healthy Subjects. Br J Clin Pharmacol. 2006;61:398-404

  111. Houghton CM, Woodcock AA, Singh SD. A comparison of plethysmography, spirometry and oscillometry for assessing the pulmonary effects of inhaled Ipratropium Bromide In Healthy Subjects And Patients With Asthma. Br J Clin Pharmacol. 2005;59:152-9

  112. Borrill ZL, Starkey C, Vestbo J, Singh SD. Reproducibility Of Exhaled Breath Condensate pH In Chronic Obstructive Pulmonary Disease. Eur Respir J. 2005;25:269-74

  113. Borrill ZL, Houghton CM, Woodcock AA, Vestbo J, Singh SD. Measuring bronchodilation in COPD clinical trials. Br J Clin Pharmacol. 2005;59:379-84

  114. Langley SJ, Houghton CM, Singh SD. Bronchoprotective and bronchodilator effects of an HFA pMDI vs. a CFC pMDI and a DPI containing formoterol in asthma patients. Respiration. 2005;72:S35-7

  115. Singh SD, Alexander J, Owen A, Rustom R, Bone M, Hammad A, Roberts N, Park BK, Pirmohamed M. Cyclosporin resistance in stable renal transplant patients; Inhibition of cell proliferation in whole blood ex-vivo is related to the expression of P-Glycoprotein. Transplantation. 2004;77:557-561

  116. Houghton CM, Langley SJ, Singh SD, Holden J, Monici Preti AP, Acerbi D, Poli G, Woodcock AA. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study. Br J Clin Pharmacol. 2004;58:359-66.

  117. Houghton CM, Woodcock AA, Singh SD. A comparison of lung function methods for assessing dose-response effects of salbutamol. Br J Clin Pharmacol. 2004;58:134-41.

  118. Singh SD, Whale C, Houghton N, Daley-Yates P, Kirby SM, Woodcock AA. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary disease and healthy volunteers: a randomised crossover study. Br J Clin Pharmacol. 2003;55:375-81 

  119. Singh SD, Woodcock AA, Booth CG. Oral prednisolone inhibits tuberculin stimulated lymphocyte proliferation in whole blood but not the tuberculin skin test in healthy subjects. Int J Pharmaceut Med. 2003;17:131-136

  120. Singh SD, Booth CG. Tuberculin induced lymphocyte proliferation in whole blood: an antigen specific method for assessing immunosuppressive agents. J Immunol Methods. 2002;260:149-156

  121. Singh SD, Sutton CJ, Woodcock AA. The variability of the measurement of the tuberculin test. Chest. 2002;122:1299-1301

  122. Singh SD, Sutton CJ, Woodcock AA. Repeat tuberculin testing in BCG vaccinated subjects in the UK: the booster effect varies with the time of reading. Am J Respir Crit Care Med. 2001;164:962-964

  123. Singh SD, Williams AJ. The prevalence and incidence of medical conditions in pharmaceutical company employees who volunteer to participate in research. Br J Clin Pharmacol. 1999;48:25-31

Reviews (peer reviewed)

  1. Singh D. New combination bronchodilators for COPD: current evidence and future perspectives. Br J Clin Pharmacol. 2014 Nov 6. doi: 10.1111/bcp.12545. [Epub ahead of print]

  2. Gupta V, Singh D. Critical assessment of the value of sputum neutrophils. COPD. 2013;10:107-14

  3. Loukides S, Bartziokas K, Vestbo J, Singh D. Novel anti-inflammatory agents in COPD: targeting lung and systemic inflammation. Curr Drug Targets. 2013;14:235-45.

  4. Gupta V, Singh D. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Expert Rev Respir Med. 2012;6:581-8

  5. Borrill ZL, Roy K, Singh SD. Exhaled breath condensate biomarkers in COPD. Eur Respir J. 2008;32:472-86.

  6. Bhowmick B, Singh SD. Novel anti-inflammatory treatments for asthma. Expert Review of Respiratory Medicine 2008;2:617-629

  7. Singh SD. Salmeterol/fluticasone propionate combination in the treatment of COPD. Expert Review of Respiratory Medicine 2007;1:25-33

Research Letters

Borrill ZL, Smith JA, Naylor J, Woodcock AA, Singh SD. The effect of gas standardisation on exhaled breath condensate pH.  Eur Respir J. 2006;28:251-2


  1. Singh D. Reduced antibacterial immunity in chronic obstructive pulmonary disease: a key role for lymphocytes? Am J Respir Crit Care Med. 2014;190:3-4

  2. Singh D. P38 inhibition in COPD; cautious optimism. Thorax. 2013;68:705-6

  3. Singh D Airway inflammation in asthma: multiple roles for thymic stromal lymphopoietin. Chest. 2012; 142:11-13 

  4. Singh SD. Tiotropium; more knowledge leads to more questions. Int J Chron Obstruct Pulmon Dis. 2008;3:i-ii

  5. Russell R, Singh SD. Which bronchodilator in COPD? Int J Chron Obstruct Pulmon Dis. 2007;2:93-4

  6. Singh SD. The benefits of combined treatment with corticosteroids and long-acting beta agonists. Int J Chron Obstruct Pulmon Dis. 2006;1:207-208

31 Jan 2017

Visit us at DIA Euromeeting

29th - 31st March at SECC, Glasgow


and BIO International Convention

19th - 22nd June in San Diego


11 Nov 2015

Sir Alex Ferguson opens new Bronchoscopy unit at MEU


2 Oct 2015

MEU-Partnership project (KTP008776) nominated for KTP Awards 2015


1 Oct 2015

Watch Professor Singh speaking about COPD Patients and the importance of reducing the risk of exacerbations at ERS 2015 in Amsterdam.


1 Oct 2015

Verona Pharma’s respiratory drug proves positive in study


25 Sept 2015

The new bronchoscopy unit at UHSM, funded by the MEU is now in operation allowing the MEU to increase its bronchoscopy capacity. The unit will be officially opened by Sir Alex Ferguson on Mon 9th November 2015



22 October 2014

The MEU and Knowledge Transfer Partnership work has been chosen as an example of excellence in the

"North West Innovation case book" - see page 19


24 June 2014

2014 World Asthma day

Listen to John Goddard, Volunteer Services Advisor, interview on Wythenshawe FM for World Asthma day


11 February 2014

MEU Clinical Physiology Manager receives John Coates award at ARTP conference gala dinner.



11 May 2012

“The MEU are pleased to announce the completion of our new extension, expanding the total bed capacity from 18 to 36, increasing our out-patient facilities, doubling the size of the volunteer lounge and extending first floor offices.”


5 August 2011

The MEU is pleased to announce that we are now accredited with the ISO9001:2008 Quality Management Systems award.


7 November 2010

Wythenshawe Hospital COPD Day

Listen to Maggie Adu, Volunteer Services Advisor, talking about the COPD Day.



 © Copyright Notice   Developed by the Barsbank Group
 Privacy Policy       Sitemap   Maintained by Amita (UK) Limited